Standout Papers

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Ca... 2022 2026 2023 2024113
  1. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer (2022)
    Jaleh Fallah, Sundeep Agrawal et al. Clinical Cancer Research

Immediate Impact

8 by Nobel laureates 18 from Science/Nature 57 standout
Sub-graph 1 of 23

Citing Papers

Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
2024 Standout
Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
1 intermediate paper

Works of Shenghui Tang being referenced

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer
2022 Standout
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer
2020
and 1 more

Author Peers

Author Last Decade Papers Cites
Shenghui Tang 2809 1763 817 1156 115 5.1k
Julia A. Beaver 2572 1414 1014 1069 129 4.5k
Kirsten B. Goldberg 2625 1239 687 949 66 4.3k
René Bruno 2719 1005 678 891 126 4.6k
M. Marty 3474 1002 1344 1361 127 6.1k
Lin Wu 2563 2037 1292 1388 217 4.9k
Boštjan Šeruga 4311 1795 1594 1142 123 7.2k
Anthony M. Magliocco 1752 1038 835 1317 136 4.1k
Antonio Jimeno 3026 1401 906 2290 128 5.1k
Jean‐Philippe Spano 2910 1183 532 1100 189 4.9k
Sophie Postel‐Vinay 3110 1651 913 2143 115 5.5k

All Works

Loading papers...

Rankless by CCL
2026